Abstract
Recent advances in biologic therapy have revolutionized the treatment of psoriasis. Risankizumab, a humanized monoclonal antibody targeting interleukin 23A, is the newest Food and Drug Administration (FDA)-approved biologic agent for the treatment of moderate-to-severe plaque psoriasis. Due to its potential immunomodulating effect, considerations for serious infections such as hepatitis B (HBV) and hepatitis C (HCV) are important when initiating biologic therapy; in particular, the serious complications of HBV and HCV reactivation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
